cisplatină, nivolumab
Nivolumab în combinație cu cisplatină și gemcitabină este aprobat de USFDA pentru carcinomul urotelial nerezecabil sau metastatic
March 2024: The Food and Drug Administration has granted approval for the use of nivolumab (Opdivo, Bristol-Myers Squibb Company) in conjunction with cisplatin and gemcitabine as the initial treatment for adult patients with unres..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv cu pembrolizumab este aprobat de USFDA pentru carcinomul urotelial local avansat sau metastatic
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
Bristol Myers Squibb, CHECKMATE-274, nivolumab, Minunat, Carcinom urotelial
Nivolumab a fost aprobat de FDA pentru a fi utilizat ca tratament adjuvant pentru carcinomul urotelial
August 2021: Nivolumab (Opdivo, Bristol-Myers Squibb Co.) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence following rad..
Astellas Pharma US, NCT03474107, Cascadele, Trial EV-301
FDA a dat aprobarea enfortumab vedotin-ejfv pentru tratamentul carcinomului urotelial local avansat sau metastatic
August 2021: Enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor combination, has been approved by the Food and Drug Administration for adult patients with locally adv..
Immunomedics Inc., mUC, platinum-containing chemotherapy, programmed death receptor-1, sacituzumab govitecan, Trodelvy, TROFEUL
Sacituzumab govitecan primește aprobare rapidă de la FDA pentru cancerul urotelial avansat
August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally advanced or metastatic urothelial cancer (mUC) who had previously receiv..